Skip to main content

Table 2 Urinary evaluation of the participants

From: The effect of mirabegron, used for overactive bladder treatment, on female sexual function: a prospective controlled study

Group A

Pre-observation

Post-observation

P value

Frequency

11.0 (1.0)

11.0 (1.0)

0.200

Urgency episodes

6.5 (1.0)

7.0 (1.0)

0.093

Nocturia episodes

2.0 (1.0)

1.0 (1.0)

0.231

Incontinence episodes

2.0 (1.0)

2.0 (2.0)

0.332

Incontinence pads

5.0 (2.0)

5.0 (2.0)

0.231

Voided volume (ml)

121.5 (31.0)

114.5 (27.0)

0.001

Group B

Pre-treatment

Post-treatment

P value

Frequency

11.0 (2.0)

9.0 (2.0)

< 0.001

Urgency episodes

7.0 (2.0)

4.0 (2.0)

< 0.001

Nocturia

2.0 (1.0)

1.0 (1.0)

< 0.001

Incontinence episodes

2.0 (1.0)

1.0 (1.0)

< 0.001

Incontinence pads

4.0 (2.0)

2.0 (2.0)

< 0.001

Voided volume (ml)

117.0 (33.0)

148.0 (26.0)

< 0.001